Abstract
Recent evidence indicates that cannabinoid-1 (CB1) receptors play a role in the mediation of opiate reward, though the neural mechanisms for this process have not been characterized. The present experiments investigated the influence of CB1 receptors in the ventral striatopallidal system on opiate-induced neurochemical events and opiate self-administration behavior in rats. Acute morphine administration (3 mg/kg) significantly reduced ventral pallidal GABA efflux in a manner similar to that produced by heroin self-administration. This neurochemical effect was reversed by doses of the selective CB1 antagonist SR 141716A (Rimonabant; 1 and 3 mg/kg) that also significantly reduce opiate reward. Morphine-induced increases in nucleus accumbens dopamine levels were unaltered by SR 141716A. Intravenous heroin self-administration (0.02 mg/infusion) was significantly reduced by intra-accumbens, but not intraventral pallidal SR 141716A infusions (1 and 3 μg/side), implicating nucleus accumbens CB1 receptors in the modulation of opiate reinforcement. In contrast, SR14716A did not alter cocaine self-administration (0.125 mg/inf), cocaine-induced (10 mg/kg) decrements in ventral pallidal GABA efflux or cocaine-induced increases in accumbens dopamine. This is consistent with evidence that selective inactivation of CB1 receptors reduces opiate-, but not psychostimulant-maintained self-administration. The CB1 receptor agonist WIN 55,212-2 (5 mg/kg) reduced pallidal GABA efflux in a manner similar to morphine, and this effect was reversed by the opiate receptor antagonist naloxone. Collectively these findings suggest that CB1 receptors modulate opiate reward through the ventral striatopallidal projection and that the modulation of this projection system may be involved in the reciprocal behavioral effects between cannabinoids, and opioids.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bardo MT (1998). Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 12: 37–67.
Bourdelais A, Kalivas PW (1990). Amphetamine lowers extracellular GABA concentration in the ventral pallidum. Brain Res 516: 132–136.
Bourdelais A, Kalivas PW (1992). Apomorphine decreases extracellular GABA in the ventral pallidum of rats with 6-OHDA lesions in the nucleus accumbens. Brain Res 577: 306–311.
Caillé S, Parsons LH (2003). SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in the nucleus accumbens in rats. Eur J Neurosci 18: 3145–3149.
Caillé S, Parsons LH (2004). Intravenous heroin self-administration decreases GABA efflux in the ventral pallidum: an in vivo microdialysis study in rats. Eur J Neurosci 20: 593–596.
Caine SB, Lintz R, Koob GF (1993). Intravenous drug self-administration techniques in animals. In: Sahgal, A (ed). Behavioural Neuroscience: A Practical Approach. Oxford University Press, New York. pp 117–143.
Chang HT, Kitai ST (1985). Projection neurons of the nucleus accumbens: an intracellular labeling study. Brain Res 347: 112–116.
Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, Sexton T et al (1992). Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann N Y Acad Sci 654: 33–51.
Corchero J, Manzanares J, Fuentes JA (2004). Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 16: 159–172.
Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M et al (2001). Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118: 61–65.
David V, Durkin TP, Cazala P (2002). Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens. Psychopharmacology (Berlin) 160: 307–317.
De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN (2003). Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology (Berlin) 168: 164–169.
De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J et al (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7: 1151–1154.
Fattore L, Cossu G, Spano MS, Delana S, Fadda P, Scherma M et al (2004). Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 16: 147–158.
Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W (1999). CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behav Brain Res 104: 141–146.
Fattore L, Spano MS, Cossu G, Deiana S, Fratta W (2003). Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17: 1723–1726.
Frantz KJ, Hansson KJ, Stouffer DG, Parsons LH (2002). 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology 42: 170–180.
French ED, Dillon K, Wu X (1997). Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8: 649–652.
Gerrits MA, Van Ree JM (1996). Effect of nucleus accumbens dopamine depletion on motivational aspects involved in initiation of cocaine and heroin self-administration in rats. Brain Res 713: 114–124.
Gessa GL, Casu MA, Carta G, Mascia MS (1998b). Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A. Eur J Pharmacol 355: 119–124.
Gessa GL, Melis M, Muntoni AL, Diana M (1998a). Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341: 39–44.
Gong W, Neill D, Justice Jr JB (1996). Conditioned place preference and locomotor activation produced by injection of psychostimulants into ventral pallidum. Brain Res 707: 64–74.
Groenewegen HJ, Russchen FT (1984). Organization of the efferent projections of the nucleus accumbens to pallidal, hypothalamic, and mesencephalic structures: a tracing and immunohistochemical study in the cat. J Comp Neurol 223: 347–367.
Groenewegen HJ, Wright CI, Beijer AV, Voor P (1999). Convergence and segregation of ventral striatal inputs and outputs. Ann NY Acad Sci. 877: 49–63.
Hakan RL, Henriksen SJ (1989). Opiate influences on nucleus accumbens neuronal electrophysiology: dopamine and non-dopamine mechanisms. J Neurosci 9: 3538–3546.
Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I et al (2000). Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 12: 3239–3249.
Hemby SE, Martin TJ, Co C, Dworkin SI, Smith JE (1995). The effects of intravenous heroin administration on extracellular nucleus accumbens dopamine concentrations as determined by in vivo microdialysis. J Pharmacol Exp Ther 273: 591–598.
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563–583.
Hoffman AF, Lupica CR (2001). Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. J Neurophysiol 85: 72–83.
Johnson PI, Stellar JR (1994). Comparison of delta opiate receptor agonist induced reward and motor effects between the ventral pallidum and dorsal striatum. Neuropharmacology 33: 1171–1182.
Johnson PI, Stellar JR, Paul DA (1993). Regional reward differences within the ventral pallidum are revealed by microinjections of a mu opiate receptor agonist. Neuropharmacology 32: 1305–1314.
Johnson SW, North RA (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483–488.
Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401–404.
Lee RS, Criado JR, Koob GF, Henriksen SJ (1999). Cellular responses of nucleus accumbens neurons to opiate-seeking behavior: I. Sustained responding during heroin self-administration. Synapse 33: 49–58.
Manzoni OJ, Bockaert J (2001). Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. Eur J Pharmacol 412: R3–R5.
Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12: 4038–4046.
Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G et al (2001). Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132: 1809–1816.
Mason Jr DJ, Lowe J, Welch SP (1999). Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol 378: 237–248.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564.
Napier TC, Mitrovic I (1999). Opioid modulation of ventral pallidal inputs. Ann NY Acad Sci 877: 176–201.
Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344–5350.
Olds ME (1982). Reinforcing effects of morphine in the nucleus accumbens. Brain Res 237: 429–440.
Panagis G, Miliaressis E, Anagnostakis Y, Spyraki C (1995). Ventral pallidum self-stimulation: a moveable electrode mapping study. Behav Brain Res 68: 165–172.
Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic: San Diego.
Pettit HO, Ettenberg A, Bloom FE, Koob GF (1984). Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacology (Berlin) 84: 167–173.
Pickel VM, Chan J, Kash TL, Rodriguez JJ, MacKie K (2004). Compartment-specific localization of cannabinoid 1 (CB1) and micro-opioid receptors in rat nucleus accumbens. Neuroscience 127: 101–112.
Pistis M, Muntoni AL, Pillolla G, Gessa GL (2002). Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study. Eur J Neurosci 15: 1795–1802.
Platt DM, Rowlett JK, Spealman RD (2001). Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms. J Pharmacol Exp Ther 299: 760–767.
Pontieri FE, Tanda G, Di Chiara G (1995). Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the ‘shell’ as compared with the ‘core’ of the rat nucleus accumbens. Proc Natl Acad Sci USA 92: 12304–12308.
Reisine T, Law SF, Blake A, Tallent M (1996). Molecular mechanisms of opiate receptor coupling to G proteins and effector systems. Ann NY Acad Sci 780: 168–175.
Rice OV, Gordon N, Gifford AN (2002). Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice. Brain Res 945: 135–138.
Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ (2001). Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 21: 109–116.
Robbe D, Alonso G, Manzoni OJ (2003). Exogenous and endogenous cannabinoids control synaptic transmission in mice nucleus accumbens. Ann NY Acad Sci 1003: 212–225.
Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ (2002). Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 99: 8384–8388.
Roberto M, Schweitzer P, Madamba SG, Stouffer DG, Parsons LH, Siggins GR (2004). Acute and chronic ethanol alter glutamatergic transmission in rat central amygdala: an in vitro and in vivo analysis. J Neurosci 24: 1594–1603.
Robledo P, Koob GF (1993). Two discrete nucleus accumbens projection areas differentially mediate cocaine self-administration in the rat. Behav Brain Res 55: 159–166.
Sesack SR, Pickel VM (1990). In the rat medial nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in apposition to each other. Brain Res 527: 266–279.
Shippenberg TS, Elmer GI (1998). The neurobiology of opiate reinforcement. Crit Rev Neurobiol 12: 267–303.
Smith AD, Bolam JP (1990). The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13: 259–265.
Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR (2003). The cannabinoid CB1 antagonist SR-141716A, differentially alters the reinforcing effects of heroin under continuous-reinforcement, fixed-ratio and progressive-ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306: 93–102.
Tanda G, Pontieri FE, Di Chiara G (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048–2050.
Tzavara ET, Wade M, Nomikos GG (2003). Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action. J Neurosci 23: 9374–9384.
Vaccarino FJ, Bloom FE, Koob GF (1985). Blockade of nucleus accumbens opiate receptors attenuates intravenous heroin reward in the rat. Psychopharmacology (Berlin) 86: 37–42.
Valverde O, Noble F, Beslot F, Dauge V, Fournie-Zaluski MC, Roques BP (2001). Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13: 1816–1824.
Van Der Kooy D, Mucha RF, O'Shaughnessy M, Bucenieks P (1982). Reinforcing effects of brain microinjections of morphine revealed by conditioned place preference. Brain Res 243: 107–117.
Vlachou S, Nomikos GG, Panagis G (2003). WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. Behav Brain Res 141: 215–222.
Welch SP, Eads M (1999). Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 848: 183–190.
Wise RA, Leone P, Rivest R, Leeb K (1995). Elevations of nucleus accumbens dopamine and DOPAC levels during intravenous heroin self-administration. Synapse 21: 140–148.
Xi ZX, Stein EA (1999). Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. J Pharmacol Exp Ther 290: 1369–1374.
Xi ZX, Stein EA (2000). Increased mesolimbic GABA concentration blocks heroin self-administration in the rat. J Pharmacol Exp Ther 294: 613–619.
Xi ZX, Stein EA (2002). GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol 37: 485–494.
Yang CR, Mogenson GJ (1989). Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens. Brain Res 489: 237–246.
Acknowledgements
This manuscript is publication 16929-NP from The Scripps Research Institute. We thank David Stouffer for his excellent technical assistance and Mike Arends for editorial assistance. We also thank Drs George F Koob and Paul J Kenny for critical comments on this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Caillé, S., Parsons, L. Cannabinoid Modulation of Opiate Reinforcement through the Ventral Striatopallidal Pathway. Neuropsychopharmacol 31, 804–813 (2006). https://doi.org/10.1038/sj.npp.1300848
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300848
Keywords
This article is cited by
-
D3 dopamine receptors and a missense mutation of fatty acid amide hydrolase linked in mouse and men: implication for addiction
Neuropsychopharmacology (2020)
-
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date
Drugs (2020)
-
Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats
Acta Pharmacologica Sinica (2019)
-
NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted
Neuropsychopharmacology (2019)
-
Endocannabinoid Regulation of Reward and Reinforcement through Interaction with Dopamine and Endogenous Opioid Signaling
Neuropsychopharmacology (2018)
